EP4117668A4 - COMPOSITION AND METHOD FOR THE ORAL TREATMENT OF LEUKEMIA - Google Patents
COMPOSITION AND METHOD FOR THE ORAL TREATMENT OF LEUKEMIA Download PDFInfo
- Publication number
- EP4117668A4 EP4117668A4 EP21935450.3A EP21935450A EP4117668A4 EP 4117668 A4 EP4117668 A4 EP 4117668A4 EP 21935450 A EP21935450 A EP 21935450A EP 4117668 A4 EP4117668 A4 EP 4117668A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- leukemia
- composition
- oral treatment
- oral
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000032839 leukemia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/027702 WO2022220841A1 (en) | 2021-04-16 | 2021-04-16 | Composition and method for oral treatment of leukemia |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4117668A1 EP4117668A1 (en) | 2023-01-18 |
EP4117668A4 true EP4117668A4 (en) | 2023-12-06 |
Family
ID=83640921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21935450.3A Pending EP4117668A4 (en) | 2021-04-16 | 2021-04-16 | COMPOSITION AND METHOD FOR THE ORAL TREATMENT OF LEUKEMIA |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4117668A4 (es) |
JP (1) | JP2023529262A (es) |
KR (1) | KR20230171854A (es) |
CN (1) | CN115955969A (es) |
AU (1) | AU2021440597A1 (es) |
CA (1) | CA3175637A1 (es) |
MX (1) | MX2022012945A (es) |
WO (1) | WO2022220841A1 (es) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002005812A1 (en) * | 2000-07-14 | 2002-01-24 | Photogen, Inc. | Medicaments for chemotherapeutic treatment of disease |
KR20070022308A (ko) * | 2004-05-10 | 2007-02-26 | 로버트 에프 호프만 | 암 치료용 약제학적 조성물 |
US20190350893A1 (en) * | 2018-05-16 | 2019-11-21 | Provectus Pharmatech, Inc. | In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102482347B (zh) * | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
US8765725B2 (en) * | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
WO2018047917A1 (ja) * | 2016-09-09 | 2018-03-15 | 国立大学法人 東京大学 | Hmgタンパク質と抗cd4抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果 |
JP2020516649A (ja) * | 2017-04-12 | 2020-06-11 | オーラ バイオサイエンシーズ, インコーポレイテッド | 標的化併用療法 |
WO2018195450A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
-
2021
- 2021-04-16 AU AU2021440597A patent/AU2021440597A1/en active Pending
- 2021-04-16 CN CN202180038959.2A patent/CN115955969A/zh active Pending
- 2021-04-16 JP JP2022562946A patent/JP2023529262A/ja active Pending
- 2021-04-16 WO PCT/US2021/027702 patent/WO2022220841A1/en unknown
- 2021-04-16 CA CA3175637A patent/CA3175637A1/en active Pending
- 2021-04-16 EP EP21935450.3A patent/EP4117668A4/en active Pending
- 2021-04-16 KR KR1020227039851A patent/KR20230171854A/ko active Search and Examination
- 2021-04-16 MX MX2022012945A patent/MX2022012945A/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002005812A1 (en) * | 2000-07-14 | 2002-01-24 | Photogen, Inc. | Medicaments for chemotherapeutic treatment of disease |
KR20070022308A (ko) * | 2004-05-10 | 2007-02-26 | 로버트 에프 호프만 | 암 치료용 약제학적 조성물 |
US20190350893A1 (en) * | 2018-05-16 | 2019-11-21 | Provectus Pharmatech, Inc. | In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors |
Non-Patent Citations (2)
Title |
---|
See also references of WO2022220841A1 * |
SWIFT LUCY ET AL: "In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 5207, XP086592718, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-119438 * |
Also Published As
Publication number | Publication date |
---|---|
MX2022012945A (es) | 2023-03-16 |
JP2023529262A (ja) | 2023-07-10 |
AU2021440597A1 (en) | 2022-11-10 |
KR20230171854A (ko) | 2023-12-21 |
WO2022220841A1 (en) | 2022-10-20 |
EP4117668A1 (en) | 2023-01-18 |
CN115955969A (zh) | 2023-04-11 |
CA3175637A1 (en) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4096675A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LONG COVID | |
EP4098260A4 (en) | ORAL PREPARATION OF EOMEPRAZOLE AND METHOD FOR PRODUCTION THEREOF | |
EP4034082A4 (en) | IMMEDIATE RELEASE ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF WEIGHT LOSS | |
EP4117668A4 (en) | COMPOSITION AND METHOD FOR THE ORAL TREATMENT OF LEUKEMIA | |
EP4045063A4 (en) | COMPOSITION AND METHODS OF TREATMENT OF MULTIPLE SCLEROSIS | |
EP4138862A4 (en) | COMPOSITIONS AND METHODS FOR TREATING UPPER AIRWAY INFECTIONS | |
EP3999077A4 (en) | COMPOSITION AND METHOD OF TREATING DIABETES | |
EP4051260A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
EP3976115A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HEMOCHROMATOSIS | |
EP3958876A4 (en) | CANCER TREATMENT COMPOSITIONS AND METHODS | |
EP3911358A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
AU2020901796A0 (en) | Compositions and methods for treatment | |
AU2022902622A0 (en) | Methods of treatment and related compositions | |
AU2023900242A0 (en) | Combination compositions and methods for treatment of Muscular Dystrophy | |
AU2020900813A0 (en) | Methods of treatment and related compositions | |
AU2020900586A0 (en) | Methods of treatment and related compositions | |
EP4103200A4 (en) | METHOD OF TREATMENT USING META-ARSENITE | |
AU2022903523A0 (en) | Compositions and methods for improved cancer treatment | |
AU2021900204A0 (en) | Method of treatment | |
AU2021901782A0 (en) | Antiviral composition, kit and method of treatment | |
AU2023903893A0 (en) | Method of treatment | |
AU2023903544A0 (en) | Methods and compositions for treating skin | |
AU2023901658A0 (en) | Method of Treatment | |
AU2023901529A0 (en) | Method of Treatment | |
AU2023901341A0 (en) | Method of Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221014 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231108 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/02 20060101ALI20231102BHEP Ipc: A61K 45/06 20060101ALI20231102BHEP Ipc: A61K 31/522 20060101AFI20231102BHEP |